Eltrombopag ITP denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for eltrombopag itp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Issues a Quantity-Limit Denial for Eltrombopag in ITP

A quantity-limit denial means the amount of eltrombopag dispensed — measured in tablets, days' supply, or dosing units per fill or per month — exceeded the quantity UHC's plan allows under its standard coverage policy. For eltrombopag in ITP, dosing is individualized and titrated to platelet response, which means a patient may legitimately require a quantity that falls outside the plan's default limit. UHC's quantity limit is set based on the typical dose range described in the FDA label, but individual patients who require titration to a higher dose or who fill a longer supply than the standard fill cycle will often hit this cap.

## Why This Denial Is Appealable

Quantity-limit policies are not absolute. Plans are required to have an exceptions process for medically necessary quantities that exceed the standard limit. Under ACA §2719, you have the right to internal appeal and external review for any coverage denial, including quantity-limit denials. Under ERISA §503, employer-plan members are entitled to a full-and-fair review. You generally have 180 days from the denial date to file an internal appeal, and approximately 4 months after a final internal denial to request external review. Expedited review is available when a delay in medication would place health at serious risk.

## Concrete Appeal Steps

1. Identify the specific limit applied: The denial letter or EOB should state the maximum quantity allowed. Note the difference between what was prescribed and what the plan allows. 2. Request a quantity-limit exception through UHC's pharmacy prior-authorization process, with clinical documentation supporting the prescribed quantity. 3. File an internal appeal if the exception is denied, with a prescriber letter providing the clinical rationale. 4. Escalate to external review if the plan upholds the denial after internal appeal.

## Documentation to Gather

• Prescriber medical-necessity letter: the treating hematologist should explain the clinical rationale for the prescribed quantity — for example, that the patient has been titrated to a specific dose based on platelet response, and that the requested supply is consistent with the FDA-approved dose range and prescribing label.
• Titration history: chart documentation showing the dose-adjustment history, platelet count response at each dose level, and the current stable or optimized dose.
• FDA prescribing label: the label describes the titration range for ITP. If the prescribed quantity is within the label's guidance, include the relevant label language.
• Platelet monitoring records: recent lab results showing how the current dose is achieving the target platelet range, supporting that the dose is both necessary and appropriate.

## Criteria-Mapping Structure

| Quantity Exception Criterion | Supporting Evidence | |---|---| | Prescribed quantity is within FDA-approved dose range | FDA label titration section (attached) | | Clinical rationale for quantity exceeding plan default | Prescriber letter explaining individual dose titration | | Platelet response supports current dose level | Lab records with dates showing response to current dose | | Supply requested matches standard fill cycle | Pharmacy prescription details |

The FDA-approved prescribing label for eltrombopag specifies the dose-titration guidance for ITP management. Ensure the prescribed quantity is explicitly anchored to that label, and obtain the UHC quantity-limit exception policy to address every criterion. Document all platelet monitoring that supports the current individualized dose.